The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer
Open accessAbstract
Drug resistance is a serious impediment in treating cancer. However, the mechanisms involved remain poorly understood. While it is widely held that the phenomenon is genetic in nature, emerging evidence suggests that non-genetic mechanisms may also be important. Furthermore, at least in some cases, refractoriness to treatment can be reversed by epigenetic reprogramming, and combination and intermittent therapy, as opposed to sustained monotherapy, appear more effective in attenuating it. Here, we iterate the confusion in understanding the phenomenon by which cancer cells evade drug response, and underscore the need to recognize the genetic/non-genetic duality of drug resistance in cancer. We discuss how ecological and evolutionary principles may help reconcile the duality, and may even offer new treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
A gene complex controlling segmentation in Drosophila
Lewis, E. B. (1978) · Nature · doi:10.1038/276565a0 · Cited by 3,812
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,449
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
Waddington, C. H. (2014) · doi:10.4324/9781315765471 · Cited by 2,153
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340 · cited 1×
“While some stochastic rewiring events will be inconsequential (the so-called ‘passengers’ in cancer genetic parlance), others will confer fitness and be selected (the so-called ‘drivers’), and can give rise to persisters (17, 19).”
BackgroundRare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · cited 7×
“Surprisingly, Shaffer et al found no evidence for the heritable, pre-resistant phenotype meaning there were no mutations in response drug treatment.”
BackgroundResultInfluentialPhenotypic plasticity and evolution by genetic assimilation
Pigliucci, M., Murren, C. J., & Schlichting, C. D. (2006) · Journal of Experimental Biology · doi:10.1242/jeb.02070 · Cited by 1,122
Canalization of Development and Genetic Assimilation of Acquired Characters
WADDINGTON, C. H. (1959) · Nature · doi:10.1038/1831654a0 · Cited by 1,094
Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3658 · Cited by 846
Fitness and its role in evolutionary genetics
Orr, H. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2603 · Cited by 695
Tumorigenesis: it takes a village
Tabassum, D. P., & Polyak, K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3971 · Cited by 564
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
GENETIC ASSIMILATION OF THE BITHORAX PHENOTYPE
Waddington, C. H. (1956) · Evolution · doi:10.1111/j.1558-5646.1956.tb02824.x · Cited by 340
Waddington, C. H. (1961) · Advances in Genetics · doi:10.1016/s0065-2660(08)60119-4 · Cited by 336
Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL
Salgia, R., Li, J.-L., Lo, S. H., Brunkhorst, B., Kansas, G. S., Sobhany, E. S., Sun, Y., Pisick, E., Hallek, M., Ernst, T., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5039 · Cited by 267
Self-citationGoldman, A., Majumder, B., Dhawan, A., Ravi, S., Goldman, D., Kohandel, M., Majumder, P. K., & Sengupta, S. (2015) · Nature Communications · doi:10.1038/ncomms7139 · Cited by 260
Su, Y., Wei, W., Robert, L., Xue, M., Tsoi, J., Garcia-Diaz, A., Homet Moreno, B., Kim, J., Ng, R. H., Lee, J. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712064115 · Cited by 228
Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., Murphy, L., Zahnow, C. A., Gabrielson, E., Velculescu, V. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.006 · Cited by 191
Application of Evolutionary Principles to Cancer Therapy
Enriquez-Navas, P. M., Wojtkowiak, J. W., & Gatenby, R. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1337 · Cited by 175
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
Lee, M.-C. W., Lopez-Diaz, F. J., Khan, S. Y., Tariq, M. A., Dayn, Y., Vaske, C. J., Radenbaugh, A. J., Kim, H. J., Emerson, B. M., & Pourmand, N. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404656111 · Cited by 172
Effect of Polymorphism in the Drosophila Regulatory Gene Ultrabithorax on Homeotic Stability
Gibson, G., & Hogness, D. S. (1996) · Science · doi:10.1126/science.271.5246.200 · Cited by 169
Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned
Santa-Maria, C. A., & Gradishar, W. J. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1198 · Cited by 126
Somatic clonal evolution: A selection-centric perspective
Scott, J. G., & Marusyk, A. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.01.006 · Cited by 91
Kulkarni, P., Jolly, M. K., Jia, D., Mooney, S. M., Bhargava, A., Kagohara, L. T., Chen, Y., Hao, P., He, Y., Veltri, R. W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700082114 · Cited by 91
Self-citationNonequilibrium Population Dynamics of Phenotype Conversion of Cancer Cells
Zhou, J., Pisco, A. O., Qian, H., & Huang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110714 · Cited by 55
Intrinsically disordered proteins and conformational noise: Implications in cancer
Mahmoudabadi, G., Rajagopalan, K., Getzenberg, R. H., Hannenhalli, S. S., Govindan Rangarajan, C., & Kulkarni, P. (2012) · Cell Cycle · doi:10.4161/cc.23178 · Cited by 55
Self-citationAnalysis of a “phase transition” from tumor growth to latency
Delsanto, P. P., Romano, A., Scalerandi, M., & Pescarmona, G. (2000) · Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics · doi:10.1103/physreve.62.2547 · Cited by 54
Kawada, I., Hasina, R., Lennon, F. E., Bindokas, V. P., Usatyuk, P. V., Tan, Y. C., Krishnaswamy, S., Arif, Q., Carey, G. B., Hseu, R. D., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.25091 · Cited by 49
Self-citationAdaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen, P., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A. J., Rosario, A. M. D., Mertins, P., Qiao, J., Schäfer, C., Gertler, F. B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 49
Salgia, R. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1181545 · Cited by 30
Self-citationDefining Resistance and Tolerance to Cancer
Dillman, A. R., & Schneider, D. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.052 · Cited by 17
Applying Tools From Evolutionary Biology to Cancer Research
Enríquez‐Navas, P. M., & Gatenby, R. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804310-3.00014-4 · Cited by 10
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Cycling cancer persister cells arise from lineages with distinct programs
Oren, Y., Tsabar, M., Cuoco, M. S., Amir-Zilberstein, L., Cabanos, H. F., Hütter, J.-C., Hu, B., Thakore, P. I., Tabaka, M., Fulco, C. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03796-6 · Cited by 502
Zhou, H.-M., Zhang, J.-G., Zhang, X., & Li, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00430-1 · Cited by 472
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Grosselin, K., Durand, A., Marsolier, J., Poitou, A., Marangoni, E., Nemati, F., Dahmani, A., Lameiras, S., Reyal, F., Frenoy, O., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0424-9 · Cited by 466
Metadata
- Authors
- Salgia, R., & Kulkarni, P.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 4
- Issue
- 2
- Pages
- 110-118
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2785797026
- Cited by
- 264
- References
- 39
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.